QC
ABCL icon

Quent Capital’s AbCellera Biologics ABCL Stock Holding History

Quent Capital’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-27,860
Closed -$128K – 1332
2023
Q3 		$128K Hold
27,860
– – 0.02% 353
2023
Q2 		$180K Hold
27,860
– – 0.03% 305
2023
Q1 		$207K Hold
27,860
– – 0.04% 272
2022
Q4 		$282K Hold
27,860
– – 0.05% 206
2022
Q3 		$276K Buy
27,860
+3,310
+13% +$36.3K 0.06% 199
2022
Q2 		$261K Hold
24,550
– – 0.06% 189
2022
Q1 		$239K Buy
24,550
+3,500
+17% +$33.1K 0.04% 241
2021
Q4 		$301K Buy
+21,050
New +$319K 0.06% 218

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return

Quent Capital's ABCL Position: Q4 2023 in Review

Quent Capital sold out of AbCellera Biologics (ABCL) in Q4 2023, closing a stake of 27,860 shares — an estimated $128K sold.

Quent Capital first reported a position in ABCL in Q4 2021 and held it in 8 quarters. The position peaked at $301K in Q4 2021. 142 funds tracked by Wall St. Rank hold ABCL as of Q4 2023.

  • Quent Capital reported no remaining AbCellera Biologics position as of Q4 2023 after selling out during the quarter.
  • Quent Capital sold 27,860 AbCellera Biologics shares in Q4 2023, an estimated $128K.
  • Quent Capital first reported a position in AbCellera Biologics in Q4 2021 and held it in 8 quarters.
  • Quent Capital's AbCellera Biologics position peaked at $301K in Q4 2021.
  • 142 funds tracked by Wall St. Rank held AbCellera Biologics as of Q4 2023.

Based on Quent Capital's 13F filing for Q4 2023, filed 19 Jan 2024.